| Ticker Details |
Curis, Inc.
Curis Inc is a biotechnology company engaged in developing and commercializing drug candidates for the treatment of human cancers. Its pipeline products include CUDC-907, CA-170, CA-4948, CA-327, and Erivedge.
|
| IPO Date: |
August 1, 2000 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$19.54M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.11 | 3.63%
|
| Avg Daily Range (30 D): |
$0.02 | 4.29%
|
| Avg Daily Range (90 D): |
$0.03 | 4.09%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.64M |
| Avg Daily Volume (30 D): |
.54M |
| Avg Daily Volume (90 D): |
.37M |
| Trade Size |
| Avg Trade Size (Sh.): |
254 |
| Avg Trade Size (Sh.) (30 D): |
459 |
| Avg Trade Size (Sh.) (90 D): |
366 |
| Institutional Trades |
| Total Institutional Trades: |
619 |
| Avg Institutional Trade: |
$1.7M |
| Avg Institutional Trade (30 D): |
$1.07M |
| Avg Institutional Trade (90 D): |
$1.07M |
| Avg Institutional Trade Volume: |
.01M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.22M |
| Avg Closing Trade (30 D): |
$M |
| Avg Closing Trade (90 D): |
$M |
| Avg Closing Volume: |
16.83K |
|
|
| Financials |
| |
TTM |
Q1 2026 |
Q4 2025 |
|
Basic EPS
|
$-.81
|
$-1.25
|
$1.61
|
|
Diluted EPS
|
$-.81
|
$-1.25
|
$1.61
|
|
Revenue
|
$7.06M
|
$M
|
$1.14M
|
|
Gross Profit
|
|
|
|
|
Net Income / Loss
|
$-21.17M
|
$-24.2M
|
$19.36M
|
|
Operating Income / Loss
|
$-7.08M
|
$-11.52M
|
$19.62M
|
|
Cost of Revenue
|
|
|
|
|
Net Cash Flow
|
$-14.94M
|
$M
|
$-14.94M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Sep 29, 2023
|
1:20
|
|
May 30, 2018
|
1:5
|
|
|
|